In The Know-February 2026

February 2026

Pdf Summary

“Ed’s List: In The Know” (February 2026) highlights notable recent gynecologic oncology research spanning prevention, screening, therapeutics, biomarkers, and trial methodology.<br /><br />Several items reinforce the impact of HPV vaccination and screening. A Swedish nationwide cohort with up to 18 years’ follow-up found sustained reduction in invasive cervical cancer after quadrivalent HPV vaccination, strongest when vaccinated before age 17, with no evidence of waning. US birth-cohort modeling showed a sharp decline in cervical cancer incidence beginning with cohorts born after 1987–1989, consistent with population-level vaccination effects and informing discussions about screening initiation age. In older US Medicare beneficiaries, cervical screening rates declined similarly in women with and without HIV, but cervical cancer/precancer prevalence increased among women with HIV, underscoring the need for guideline adherence and lifelong screening. A large Kaiser Permanente prospective study found dual-stain triage outperformed cytology for HPV-positive women, providing stronger long-term reassurance for dual-stain–negative results. For surveillance, ultrasensitive NGS detection of circulating HPV DNA predicted recurrence strongly at first post-treatment sampling and often preceded clinical recurrence.<br /><br />Multiple translational and clinical advances are featured. Integrated genomic profiling of endometrial stromal sarcoma identified actionable subsets (e.g., RAS–MAPK alterations, hypermutated tumors) and preclinical sensitivity of an NRAS-mutant model to combined MEK/FAK inhibition. In ovarian cancer, phase 3 KEYNOTE-B96 reported improved PFS with pembrolizumab plus weekly paclitaxel (± bevacizumab) in platinum-resistant disease and an OS benefit in PD-L1 CPS ≥1. Mechanistic studies suggested new combination strategies, including brigatinib (dual FAK/EPHA2) to enhance PARP inhibitor responses, and characterized metastatic biology (mesothelial-cell–assisted spheroids) and genomic heterogeneity driven by ongoing L1 retrotransposition. A spatial single-cell atlas linked tumor MHC class II expression to immune activation and better outcomes in high-grade serous ovarian cancer.<br /><br />Prevention and risk reduction themes include strong consensus support for opportunistic salpingectomy to lower tubo-ovarian cancer risk, and emerging evidence that GLP-1 receptor agonists combined with progestins may reduce endometrial cancer risk, complemented by a mechanistic review of GLP-1RAs in endometrial cancer.<br /><br />Methodology updates include debate on overall survival as a trial endpoint (crossover, post-progression therapy, and censoring) and a cautionary note about non-portable AI cervical image classifiers due to overfitting.

Keywords

HPV vaccination effectiveness

cervical cancer screening guidelines

dual-stain triage for HPV-positive women

circulating HPV DNA NGS recurrence monitoring

endometrial stromal sarcoma genomic profiling

platinum-resistant ovarian cancer pembrolizumab KEYNOTE-B96

PARP inhibitor combination therapy brigatinib FAK EPHA2

high-grade serous ovarian cancer spatial single-cell atlas MHC class II

opportunistic salpingectomy tubo-ovarian cancer prevention

overall survival endpoint debate and AI overfitting in cervical imaging